IE45768B1 - Pharmaceutical compositions containing pirbuterol and hydroxyzinc - Google Patents
Pharmaceutical compositions containing pirbuterol and hydroxyzincInfo
- Publication number
- IE45768B1 IE45768B1 IE1770/77A IE177077A IE45768B1 IE 45768 B1 IE45768 B1 IE 45768B1 IE 1770/77 A IE1770/77 A IE 1770/77A IE 177077 A IE177077 A IE 177077A IE 45768 B1 IE45768 B1 IE 45768B1
- Authority
- IE
- Ireland
- Prior art keywords
- pirbuterol
- hydroxyzine
- composition
- base
- acid addition
- Prior art date
Links
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 title claims abstract description 68
- 229960005414 pirbuterol Drugs 0.000 title claims abstract description 67
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 4
- YVZATJAPAZIWIL-UHFFFAOYSA-M [Zn]O Chemical compound [Zn]O YVZATJAPAZIWIL-UHFFFAOYSA-M 0.000 title 1
- 229960000930 hydroxyzine Drugs 0.000 claims abstract description 69
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims abstract description 68
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 239000002253 acid Substances 0.000 claims abstract description 20
- 239000012458 free base Substances 0.000 claims abstract description 4
- 239000002585 base Substances 0.000 claims description 26
- 239000002552 dosage form Substances 0.000 claims description 3
- 230000009325 pulmonary function Effects 0.000 abstract description 5
- 241000124008 Mammalia Species 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000000443 aerosol Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000003826 tablet Substances 0.000 description 9
- XIDFCZTVVCWBGN-UHFFFAOYSA-N Pirbuterol hydrochloride Chemical compound Cl.Cl.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 XIDFCZTVVCWBGN-UHFFFAOYSA-N 0.000 description 8
- 229940124630 bronchodilator Drugs 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000003380 propellant Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000168 bronchodilator agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229940039009 isoproterenol Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- -1 decanoate dihydrochloride palmitate citrate stearate dihydrochloride succinate sulfate Chemical compound 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- RFCAUADVODFSLZ-UHFFFAOYSA-N 1-Chloro-1,1,2,2,2-pentafluoroethane Chemical compound FC(F)(F)C(F)(F)Cl RFCAUADVODFSLZ-UHFFFAOYSA-N 0.000 description 1
- RILLZYSZSDGYGV-UHFFFAOYSA-N 2-(propan-2-ylamino)ethanol Chemical compound CC(C)NCCO RILLZYSZSDGYGV-UHFFFAOYSA-N 0.000 description 1
- CYXIKYKBLDZZNW-UHFFFAOYSA-N 2-Chloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)CCl CYXIKYKBLDZZNW-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 244000165918 Eucalyptus papuana Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100033213 Teneurin-1 Human genes 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000794 anti-serotonin Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000002741 bronchospastic effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000019406 chloropentafluoroethane Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229940050830 ephedrine / theophylline Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940125386 long-acting bronchodilator Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 108010063973 teneurin-1 Proteins 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71790576A | 1976-08-26 | 1976-08-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE45768L IE45768L (en) | 1978-02-28 |
| IE45768B1 true IE45768B1 (en) | 1982-11-17 |
Family
ID=24883964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1770/77A IE45768B1 (en) | 1976-08-26 | 1977-08-25 | Pharmaceutical compositions containing pirbuterol and hydroxyzinc |
Country Status (19)
| Country | Link |
|---|---|
| JP (1) | JPS5329935A (cs) |
| AU (1) | AU503877B2 (cs) |
| BE (1) | BE858094A (cs) |
| CA (1) | CA1092028A (cs) |
| DE (1) | DE2737735C3 (cs) |
| DK (1) | DK354377A (cs) |
| FR (1) | FR2362629A1 (cs) |
| GB (1) | GB1541991A (cs) |
| GR (1) | GR68687B (cs) |
| HK (1) | HK30981A (cs) |
| IE (1) | IE45768B1 (cs) |
| IL (1) | IL52588A (cs) |
| LU (1) | LU78022A1 (cs) |
| MY (1) | MY8100263A (cs) |
| NL (1) | NL170367C (cs) |
| NZ (1) | NZ184746A (cs) |
| PT (1) | PT66866B (cs) |
| SE (1) | SE7708307L (cs) |
| ZA (1) | ZA774474B (cs) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63156327U (cs) * | 1987-04-02 | 1988-10-13 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2899436A (en) * | 1959-08-11 | chjch | ||
| US3700681A (en) * | 1971-02-16 | 1972-10-24 | Pfizer | 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines |
| US3786160A (en) * | 1971-02-16 | 1974-01-15 | Pfizer | Use of 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)-pyridines as bronchodilators |
-
1977
- 1977-07-18 SE SE7708307A patent/SE7708307L/xx unknown
- 1977-07-23 GR GR54026A patent/GR68687B/el unknown
- 1977-07-25 IL IL52588A patent/IL52588A/xx unknown
- 1977-07-25 ZA ZA00774474A patent/ZA774474B/xx unknown
- 1977-07-26 NZ NZ184746A patent/NZ184746A/xx unknown
- 1977-07-28 AU AU27412/77A patent/AU503877B2/en not_active Expired
- 1977-07-29 PT PT66866A patent/PT66866B/pt unknown
- 1977-08-08 NL NLAANVRAGE7708732,A patent/NL170367C/xx not_active IP Right Cessation
- 1977-08-09 DK DK354377A patent/DK354377A/da not_active Application Discontinuation
- 1977-08-09 CA CA284,372A patent/CA1092028A/en not_active Expired
- 1977-08-22 DE DE2737735A patent/DE2737735C3/de not_active Expired
- 1977-08-23 GB GB7735281A patent/GB1541991A/en not_active Expired
- 1977-08-25 BE BE180416A patent/BE858094A/xx not_active IP Right Cessation
- 1977-08-25 JP JP10218177A patent/JPS5329935A/ja active Pending
- 1977-08-25 IE IE1770/77A patent/IE45768B1/en not_active IP Right Cessation
- 1977-08-25 LU LU78022A patent/LU78022A1/xx unknown
- 1977-08-25 FR FR7725959A patent/FR2362629A1/fr active Granted
-
1981
- 1981-07-02 HK HK309/81A patent/HK30981A/en not_active IP Right Cessation
- 1981-12-30 MY MY263/81A patent/MY8100263A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE2737735B2 (de) | 1979-03-08 |
| PT66866B (en) | 1978-12-29 |
| FR2362629B1 (cs) | 1980-07-11 |
| NZ184746A (en) | 1980-02-21 |
| NL7708732A (nl) | 1978-02-28 |
| DK354377A (da) | 1978-02-27 |
| IL52588A (en) | 1980-07-31 |
| ZA774474B (en) | 1978-06-28 |
| DE2737735A1 (de) | 1978-03-02 |
| DE2737735C3 (de) | 1979-10-25 |
| AU2741277A (en) | 1979-02-01 |
| NL170367C (nl) | 1982-11-01 |
| LU78022A1 (fr) | 1979-05-23 |
| CA1092028A (en) | 1980-12-23 |
| MY8100263A (en) | 1981-12-31 |
| IE45768L (en) | 1978-02-28 |
| BE858094A (fr) | 1978-02-27 |
| AU503877B2 (en) | 1979-09-27 |
| JPS5329935A (en) | 1978-03-20 |
| GB1541991A (en) | 1979-03-14 |
| HK30981A (en) | 1981-07-10 |
| FR2362629A1 (fr) | 1978-03-24 |
| SE7708307L (sv) | 1978-02-27 |
| PT66866A (en) | 1977-08-01 |
| IL52588A0 (en) | 1977-10-31 |
| GR68687B (cs) | 1982-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1045695B1 (en) | Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f 1? to treat peripheral vascular disease | |
| US3801631A (en) | 2'-hydroxy-5'-(1-hydroxy-2-(2-methyl-1-phenyl-2-propylamino)ethyl)meth-anesulfonanilide and its salts | |
| JPH0696521B2 (ja) | 眼局所投与用眼圧降下剤 | |
| EP0038674A1 (en) | Medicinal composition for treatment of allergic diseases | |
| GB2170707A (en) | An immuno-regulator | |
| US4861783A (en) | 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases | |
| EP0222575B1 (en) | Prazosin-pirbuterol combination for bronchodilation | |
| EP0190851B1 (en) | Improved antiinflammatory composition | |
| US3934036A (en) | N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent | |
| IE45768B1 (en) | Pharmaceutical compositions containing pirbuterol and hydroxyzinc | |
| US6660719B2 (en) | Inhibiting T-Cell proliferation | |
| US4175128A (en) | Method for treating congestive heart failure | |
| EP0037187B1 (en) | Salts and aqueous solutions of 6-methylamino-4-oxo-10-propyl-4h-pyrano(3,2-g)-quinoline-2,8-di-carboxylic acid and pharmaceutical compositions containing such salts and solutions | |
| US4623666A (en) | Pharmacological applications of diphenylhalonium ion | |
| US4714703A (en) | Method of inhibiting herpetic lesions | |
| GB2074858A (en) | Compositions containing 3-deazaaden-osine | |
| EP0650723A2 (en) | Novel pharmaceutical use of forskolin derivatives | |
| JPS648602B2 (cs) | ||
| US6015810A (en) | Aqueous ophthalmic solution containing apafant as active ingredient | |
| US4061756A (en) | Methods for treating cardiovascular disorders | |
| US3969508A (en) | Lowering the concentration of plasma triglycerides | |
| JPS632926A (ja) | 安定な、注射可能な制吐性組成物 | |
| Zwickey et al. | Preclinical toxicological studies of carbidopa and combinations of carbidopa and levodopa | |
| JPS6245525A (ja) | 脂質低下剤 | |
| US3749781A (en) | Pharmaceutical composition and method of treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK9A | Patent expired |